UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

______________

FORM 8-K

______________

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~SECTION 13 orOR 15(d) ofOF ~~the Securities Exchange Act of 1934~~THE

~~Date~~SECURITIES ofEXCHANGE ~~Report~~ACT ~~(Date~~OF ~~of earliest event reported): March 8, 2010~~1934

~~______________~~Date of report (Date of earliest event reported): March 13, 2010

~~CORDEX~~Cordex ~~PHARMA~~Pharma, ~~INC~~Inc.

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its charter~~Charter)

______________

Nevada	000-33023	86-0982792
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Nevada	000-33023	86-0982792
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

7660 Fay Avenue, Suite H-373, La Jolla, CA 92037

(Address of Principal Executive ~~Office~~Offices) (Zip Code)

Registrant’s telephone number, including area code: (858) 551-5700

(Registrant’s telephone number, including area code)

N/A

(Former ~~name~~Name or ~~former~~Former ~~address~~Address, if ~~changed~~Changed ~~since~~Since ~~last~~Last ~~report~~Report)

~~Check the~~ Copies ~~appropriate box below if the Form 8-K filing is intended~~ to ~~simultaneously satisfy the filing obligation of the registrant under any of the following provisions~~:

~~¨ Written communications~~Hank ~~pursuant~~Gracin, ~~to Rule 425 under the Securities Act (17 CFR 230~~Esq.~~425)~~

~~¨ Soliciting material~~Gracin ~~pursuant~~& toMarlow, ~~Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)~~LLP

~~¨ Pre-commencement~~Suite ~~communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))~~300

~~¨ Pre-commencement~~20283 ~~communications~~State ~~pursuant~~Route ~~to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~7

~~ITEM~~Boca ~~8.01~~Raton, ~~OTHER~~Florida ~~EVENTS~~33498

(561) On March 8, 2010, the Company entered into an agreement dated as of March 4, 2010 with its debenture holders which, among other things, extended the maturity date of all of its outstanding debentures until April 30, 2010. Certain debenture holders have agreed to provide funding to the Company in the aggregate amount of $40,000, through loans to the Company, which loans are senior to all other secured loans other than the January and February 2010 loans and are on a party basis with the January 2010 and February loans.237-0804

~~ITEM~~Check ~~9.01 FINANCIAL~~the appropriate ~~STATEMENTS~~box ~~AND~~below if the Form 8-K filing is intended to simultaneously ~~EXHIBITS~~satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (a17 CFR 230.425) ~~Not applicable~~ o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~(b)~~Item 5.02. Departure ~~Not~~of Directors ~~applicable~~or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a) N/A (b) On March 13, 2010, the Company received written notice of the resignation of Dr. Jim Kuo as director of the Board of the Company, effective immediately. (c) ~~Not applicable~~ N/A (d) N/A (e) N/A (f) N/A

~~(d)~~Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
4.1		Form of Bridge Note
10.1		Extension and Bridge Funding Agreement dated March 4, 2010

(a) – (c)		N/A

(d) Exhibits.		N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORDEX PHARMA, INC. By: /s/ SHEPARD GOLDBERG Shepard Goldberg Chief Executive Officer

Date: March 16, 2010	CORDEX PHARMA, INC.


	By: /s/ Shepard Goldberg
	Name: Shepard Goldberg Title: Chief Executive Officer

Date: March 11, 2010

Filing Compare · Cordex Pharma, Inc.